The molecular connections between the cannabinoid system and endometriosis

Molecular Human Reproduction

Volumn 18, Issue 12, 2012, Pages 563-571

  Sanchez, A M ^a   Vigano, P ^a   Mugione, A ^a   Panina bordignon, P ^a   Candiani, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anandamide; Cannabinoid; Endometriosis; Endometrium

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N ACYLPHOSPHATIDYLETHANOLAMINEPHOSPHOLIPASE D; NABILONE; NABIXIMOLS; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D; PROTEIN KINASE B; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANALGESIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG MECHANISM; DRUG METABOLISM; ECTOPIC PREGNANCY; ENDOMETRIOSIS; ENDOMETRIUM; HUMAN; HYPERALGESIA; IMMUNITY; INFLAMMATION; MENSTRUAL CYCLE; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SENSORY NERVE CELL; SYMPATHETIC NERVE CELL;

ARACHIDONIC ACIDS; CANNABINOIDS; ENDOCANNABINOIDS; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; POLYUNSATURATED ALKAMIDES;

ANIMALIA;

EID: 84869436431     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gas037     Document Type: Review

References (78)

1. Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, Haro A, Velasco G, Guzman M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008;68:1945-1952.
2. Bloch E, Thysen B, Morrill GA, Gardner E, Fujimoto G. Effects of cannabinoids on reproduction and development. Vitam Horm 1978; 36:203-258.
3. Capobianco A, Monno A, Cottone L, Venneri MA, Biziato D, Di Puppo F, Ferrari S, De Palma M, Manfredi AA, Rovere-Querini P. Proangiogenic Tie(2) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease. Am J Pathol 2011;179:2651-2659.
4. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43-50.
5. Chakravarty I, Sengupta D, Bhattacharya P, Ghosh JJ. Effect of treatment with cannabis extract on the water and glyogen contects of the uterus in normal and estradiol-treated prepubertal rats. Toxic Appl Pharmac 1975;34:513-516.
6. Chung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Lake Polan M. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fertil Steril 2001;75:152-159.
7. Chung HW, Lee JY, Moon HS, Hur SE, Park MH, Wen Y, Polan ML. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril 2002;78:787-795.
8. Cox KE, Piva M, Sharpe-Timms KL. Differential regulation of matrix metalloproteinase-3 gene expression in endometriotic lesions compared with endometrium. Biol Reprod 2001;65:1297-1303.
9. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87.
10. Das SK, Paria BC, Andrews GK, Dey SK. Effects of 9-ene-tetrahydrocannabinol on expression of beta-type transforming growth factors, insulin-like growth factor-I and c-myc genes in the mouse uterus. J Steroid Biochem Mol Biol 1993;45:459-465.
11. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA 1995; 92:4332-4336.
12. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141:765-774.
13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
14. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-784.
15. Dmitrieva N, Nagabukuro H, Resuehr D, Zhang G, McAllister SL, McGinty KA, Mackie K, Berkley KJ. Endocannabinoid involvement in endometriosis. Pain 2010;151:703-710.
16. Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, Hennuyer N, Gilde A, Staels B, Schaeffer P, Bono F. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009; 29:12-18.
17. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996;393:231-235.
18. Freimuth N, Ramer R, Hinz B. Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 2010;332:336-344.
19. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, Dubinett SM. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun 2002; 290:91-96.
20. Gentilini D, Besana A, Vigano P, Dalino P, Vignali M, Melandri M, Busacca M, Di Blasio AM. Endocannabinoid system regulates migration of endometrial stromal cells via cannabinoid receptor 1 through the activation of PI3K and ERK1/2 pathways. Fertil Steril 2010;93:2588-2593.
21. Gentilini D, Perino A, Vigano' P, Chiodo I, Cucinella G, Vignali M, Di Blasio AM, Busacca M. Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases. Hum Reprod 2011; 26:3109-3117.
22. Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, Vento R, Tesoriere G. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. Biochimie 2009;91:457-465.
23. Greineisen WE, Turner H. Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. Int Immunopharmacol 2010;10:547-555.
24. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 2011;163:1447-1463.
25. Guo SW, Hummelshoj L, Olive DL, Bulun SE, D'Hooghe TM, Evers JL. A call for more transparency of registered clinical trials on endometriosis. Hum Reprod 2009;24:1247-1254.
26. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004;64:1943-1950.
27. Howard FM. Endometriosis and mechanisms of pelvic pain. J Minim Invasive Gynecol 2009;16:540-550.
28. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47(Suppl 1):345-358.
29. Huang NL, Juang JM, Wang YH, Hsueh CH, Liang YJ, Lin JL, Tsai CT, Lai LP. Rimonabant inhibits TNF-alpha-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway. Acta Pharmacol Sin 2010;31:1447-1453.
30. Joseph J, Niggemann B, Zaenker KS, Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004;53:723-728.
31. Kogan NM, Blazquez C, Alvarez L, Schlesinger M, Guzman M, Mechoulam R. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 2006;70:51-59.
32. Kokorine I, Nisolle M, Donnez J, Eeckhout Y, Courtoy PJ, Marbaix E. Expression of interstitial collagenase (matrix metalloproteinase-1) is related to the activity of human endometriotic lesions. Fertil Steril 1997;68:246-251.
33. Kondo S, Kondo H, Nakane S, Kodaka T, Tokumura A, Waku K, Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett 1998;429:152-156.
34. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008;23:2017-2023.
35. Laezza C, Pisanti S, Malfitano AM, Bifulco M. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 2008; 15:965-974.
36. Lebovic DI, Mwenda JM, Chai DC, Santi A, Xu X, D'Hooghe T. Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology 2010;151:1846-1852.
37. Leconte M, Nicco C, Ngo C, Arkwright S, Chereau C, Guibourdenche J, Weill B, Chapron C, Dousset B, Batteux F. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol 2010;177:2963-2970.
38. Leconte M, Nicco C, Ngo C, Chereau C, Chouzenoux S, Marut W, Guibourdenche J, Arkwright S, Weill B, Chapron C et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011;179:880-889.
39. Lee SF, Newton C, Widen R, Friedman H, Klein TW. Differential expression of cannabinoid (CB2) receptor mRNA in mouse immune cells subpopulation and followign B cell stimulation. Eur J Pharmacol 2001;423:235-241.
40. Liu XJ, He YL, Peng DX. Expression of metalloproteinase-9 in ectopic endometrium in women with endometriosis. Acad J First Med Coll PLA 2002;22:467-469.
41. Maccarrone M. Endocannabinoids: friends and foes of reproduction. Prog Lipid Res 2009;48:344-354.
42. McHugh D, Page J, Dunn E, Bradshaw HB. Delta(9)-THC and N-arachidonyl glycine are full agonists at GPR18 and cause migration in the human endometrial cell line, HEC-1B. Br J Pharmacol 2011; 8:2411-2413.
43. Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000; 74:760-766.
44. Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev 2011;63:461-70.
45. Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010;15:474-483.
46. Myers MP, Tonks NK. PTEN: sometimes taking it off can be better than putting it on. Am J Hum Genet 1997;61:1234-1238.
47. Nagarkatti P, Pandey R, Rieder SA, Hedge VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009;1:1333-349.
48. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Diaz-Laviada I. The cannabinoid R(+)methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J Immunotoxicol 2009;6:249-256.
49. Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002;66:307-344.
50. Paria BC, Kapur S, Dey SK. Effects of 9-ene-tetrahydrocannabinol in uterine estrogenicity in the mouse. J Steroid Biochem Mol Biol 1992;42:713-719.
51. Paria BC, Wang XN, Dey SK. Effects of chronic treatment with delta-9-tetrahydrocannabinol on uterine growth in the mouse. Life Sci 1994;55:729-734.
52. Paria BC, Zhao X, Wang J, Das SK, Dey SK. Fatty-acid amide hydrolase is expressed in the mouse uterus and embryo during the periimplantation period. Biol Reprod 1999;60:1151-1157.
53. Paria BC, Song H, Wang X, Schmid PC, Krebsbach RJ, Schmid HH, Bonner TI, Zimmer A, Dey SK. Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J Biol Chem 2001; 276:20523-20528.
54. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 1999;65:637-644.
55. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180.
56. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005;76:1307-1324.
57. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411.
58. Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, Morbidelli L, Gazzerro P, Ziche M, Das A et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 2011;117:5541-5550.
59. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003;17:1771-1773.
60. Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmun Pharmacol 2008;3:117-129.
61. Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 2010;79:955-966.
62. Resuehr D, Glore DR, Taylor HS, Bruner-Tran KL, Osteen KG. Progesterone-dependent regulation of endometrial cannabinoid receptor type 1 (CB1-R) expression is disrupted in women with endometriosis and in isolated stromal cells exposed to 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD). Fertil Steril 2012. (Epub ahead of print).
63. Rodgers WH, Osteen KG, Matrisian LM, Navre M, Giudice LC, Gorstein F. Expression and localization of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle. Am J Obstet Gynecol 1993;168:253-260.
64. Sanchez MG, Ruiz-Llorente L, Sanchez AM, Diaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 2003;15:851-9.
65. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672.
66. Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009;11:39-44.
67. Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. Hum Reprod Update 2011; 17:327-346.
68. Taylor RN, Yu J, Torres PB, Schickedanz AC, Park JK, Mueller MD, Sidell N. Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 2009;16:140-146.
69. Taylor AH, Abbas MS, Habiba MA, Konje JC. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol 2010a;133:557-565.
70. Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM, Marzcylo TH, Konje JC. Endocannabinoids and pregnancy. Clin Chim Acta 2010b;411:921-930.
71. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG. The fatty acid amide hydrolase (FAAH). Chem Phys Lipids 2000;108:107-121.
72. Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda K, Yamaguchi H, Akise D, Hung YC et al. Survivin gene expression in endometriosis. J Clin Endocrinol Met 2002;87:3452-3459.
73. Venance L, Maldonado R, Manzoni O. Endocannabinoids in the central nervous system. Med Sci 2004; 20:45-53.
74. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69:649-675.
75. Vercellini P, Crosignani PG, Somigliana E, Vigano P, Frattaruolo MP, Fedele L. Waiting for Godot a commensense approach to the medical treatment of endometriosis. Hum Reprod 2011;26:3-13.
76. Wang H, Dey SK, Maccarrone M. Jekyll and Hyde: two faces of cannabinoid signaling in male and female fertility. Endocr Rev 2006; 27:427-448.
77. Wenzl RJ, Heinzl H. Localization of matrix metalloproteinase-2 in uterine endometrium and ectopic implants. Gynecol Obstet Invest 1998;45:253-257.
78. Zhang H, Zhao X, Liu S, Li J, Wen Z, Li M. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaBdependent pathway. Mol Cell Endocrinol 2010;317:31-43.